| Country | Year | Age | FIGO | Treatment | Follow-Up (Months) | Outcome |
| Japan [53] | 2015 | 59 | II | RH, V, DTIC, IM | 5 | Lung metastases |
| Bulgaria [23] | 2014 | 71 | II | RH, V, LN IM, DTIC | 21 | Died 21 months |
| China [31] | 2014 | 35 | II | RH, LN, V | 6 | Pelvic recurrence; lost to follow-up |
| Denmark [54] | 2013 | 77 | II | exenteration | 7 | Recurrence at 7 months |
| Morrocco [51] | 2013 | 70 | IV | imatinib | 18 | regression |
| India [7] | 2013 | 60 | II | WLE, EBRT CT: TEM | 12 | Alive at one year |
| Greece [24] | 2013 | 80 | II | WLE, ICRT | 5 | Died lung metastases at one year* |
| Germany [55] | 2012 | 44 | III | exenteration | 4 | Died at 4 months |
| India [10] | 2012 | 66 | II | WLE,EBRT | 12 | Died with widespread recurrence |
| China [56] | 2011 | 54 | III | RH, V EBRT, IM, CT | 12 | Brain metastasis |
| India [6] | 2009 | 60 | II | WLE DTIC | 12 | Alive one year |
| Turkey [25] | 2009 | 51 | ! | V, LN DTIC, cispltin | 21 | Nodal metastases at 9 months Alive at 21 months |
| Bangladesh [9] | 2008 | 52 | I | WLE, EBRT | -- | Lost to follow-up |
| Nepal [8] | 2007 | 60 | II | WLE, EBRT | 6 | Recurrence 3 months Died at 6 months |
| Germany [26] | 2007 | 58 | I | WLE, EBRT | 6 | Metastasized at 6 months |
| Spain [27] | 2004 | 40 | I | RH, V, LN EBRT, IM | 8 | Recurred in liver and ascites at 7 months Died at 8 months |
| South Africa [28] | 2004 | 49 | II | WLE, IM DTIC & carboplatin | 24 | Alive at 2 years |
| Israel [29] | 2002 | 67 | II | WLE, EBRT ICRT | 11 | Alive at 11 months |
| Italy [15] | 1998 | 45 | IV | Exenteration DTIC fotemustine | 12 | Metastases at 4 months Alive at 12 months |
| USA [30] | 1998 | 55 | I | WLE, LN | 13 years | Alive at 13 years |